NTRA); The deadline for the main applicant is June 27, 2022
PHILADELPHIA CREAM, May 26, 2022 /PRNewswire/ — Shepherd Montague investigating allegations of securities fraud on behalf of investors who purchased Natera, Inc. (“Natera” or the “Company”) (NASDAQ: NTRA) securities between February 26, 2020 and April 19, 2022 (the “Class Period”).
If you purchased Natera securities during the Class Period, would like to discuss At Berger Montague investigation, or if you have any questions regarding your rights or interests, please contact the lawyers Andre Abramowitz at [email protected] or (215) 875-3015, or Michael Dell‘Angelo to [email protected] or (215) 875-3080 or visit: https://investigations.bergermontague.com/natera-inc/
Whistleblowers: Anyone with non-public information about Natera is encouraged to help confidentially. At Berger Montague survey or take advantage of the SEC Whistleblower program. Under this program, whistleblowers who provide original information may receive rewards totaling up to thirty percent (30%) of recoveries obtained by the SEC. For more information, contact us.
Natera offers genetic testing in the areas of women’s health, oncology and organ health. Among other things, the Company produces and markets a non-invasive prenatal test (NIPT), called “Panorama”, and a screening test for kidney transplant failure, called “Prospera”.
The prosecution alleges that from the January 1, 2022when The New York Times released a report questioning the accuracy of some prenatal tests made by Natera and other companies, investors learned that Natera hid that its prenatal diagnostic tests showed false positive results more than 80% of the time.
The complaint further alleges that on January 14, 2022a nonprofit watchdog called Campaign for Accountability filed a complaint with the SEC asking for an investigation into whether Natera misrepresented the accuracy of its tests in marketing materials and earnings calls.
Then, on March 9, 2022, Hindenburg Research released an investigative report alleging that Natera’s growth was fueled by deceptive sales and billing practices. Less than a week later, the March 14, 2022a jury found that Natera intentionally and deliberately misled the public by using false advertisements to market Prospera in violation of federal and state laws.
Finally, on April 19, 2022the FDA issued a safety communication warning the public that statements about the reliability and accuracy of NIPT “may not be supported by strong scientific evidence.”
In response to these disclosures, Natera’s common stock price fell significantly, resulting in losses for investors.
Shepherd Montaguewith offices at philadelphia cream, Minneapolis, washington d.c.and San Diegohas been a pioneer in securities class actions since its founding in 1970. Shepherd Montague has represented individual and institutional investors for over five decades and acts as lead counsel before courts across United States.
Andre Abramowitzsenior counsel
Michael Dell‘Angelo, executive shareholder
THE SOURCE Shepherd Montague